Somatostatin Receptor 2 and 5 Expressions in Gastroenteropancreatic Neuroendocrine Tumors in Turkey |
Yerci, Omer
(Department of Pathology, Faculty of Medicine, Uludag University)
Sehitoglu, Ibrahim (Department of Pathology, Faculty of Medicine, Recep Tayyip Erdogan University) Ugras, Nesrin (Department of Pathology, Faculty of Medicine, Uludag University) Cubukcu, Erdem (Department of Medical Oncology, Faculty of Medicine, Uludag University) Yuce, Suleyman (Department of Internal Medicine, Faculty of Medicine, Recep Tayyip Erdogan University) Bedir, Recep (Department of Pathology, Faculty of Medicine, Recep Tayyip Erdogan University) Cure, Erkan (Department of Internal Medicine, Faculty of Medicine, Recep Tayyip Erdogan University) |
1 | Akerstrom G, Hellman P (2007). Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab, 21, 87-109. DOI |
2 | Bertherat J, Tenenbaum F, Perlemoine K, et al (2003). Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab, 88, 5353-60. DOI |
3 | Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday TJ (2005). Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc, 80, 502-6. DOI |
4 | Demirkan BH, Eriksson B (2012). Systemic treatment of neuroendocrine tumors with hepatic metastases. Turk J Gastroenterol, 23, 427-37. DOI |
5 | de Sa SV, Correa-Giannella ML, Machado MC, et al (2006). Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocr Relat Cancer, 13, 69-78. DOI ScienceOn |
6 | Guo RS, Shi PD, Zhou J, Chen YY (2013). Somatostatin receptors 3, 4 and 5 play important roles in gallbladder cancer. Asian Pac J Cancer Prev, 14, 4071-5. DOI ScienceOn |
7 | Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM (2008). Pancreatic endocrine neoplasms: Epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer, 15, 409-27. DOI ScienceOn |
8 | Iida S, Miki Y, Ono K, et al (2010). Novel classification based on immunohistochemistry combined with hierarchical clustering analysis in non-functioning neuroendocrine tumor patients. Cancer Sci, 101, 2278-85. DOI |
9 | Kilickap S, Kaya Y, Yucel B, Tuncer E, Babacan NA, Elagoz S (2014). Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer. Asian Pac J Cancer Prev, 15, 1381-5. DOI |
10 | Kloppel G, Anlauf M (2005). Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol, 19, 507-17. DOI |
11 | Kloppel G, Rindi G, Anlauf M, Perren A, Komminoth P (2007). Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch, 451, 9-27. DOI |
12 | Koc EU, Ozgur T, Yerci O, Gurel S (2013). Somatostatin receptor 1 (SSTR1) and somatostatin receptor 5 (SSTR5) expression in hepatocellular carcinoma. Hepatogastroenterology, 60, 1693-7. |
13 | Lamberts SW, de Herder WW, Hofland LJ (2002). Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab, 13, 451-7. DOI |
14 | Liu SZ, Zhang F, Chang YX, et al (2013). Prognostic impact of cyclin D1, cyclin E and P53 on gastroenteropancreatic neuroendocrine tumours. Asian Pac J Cancer Prev, 14, 419-22. DOI ScienceOn |
15 | Modlin IM, Oberg K, Chung DC, et al (2008). Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol, 9, 61-72. DOI |
16 | Modlin IM, Moss SF, Oberg K, et al (2010). Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med J Aust, 193, 46-52. |
17 | Papotti M, Bongiovanni M, Volante M, et al (2002). Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch, 440, 461-75. DOI |
18 | Nakayama Y, Wada R, Yajima N, Hakamada K, Yagihashi S (2010). Profiling of somatostatin receptor subtype expression by quantitative PCR and correlation with clinicopathological features in pancreatic endocrine tumors. Pancreas, 39, 1147-54. DOI |
19 | Oberg K (2001). Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol, 12, 111-4. DOI |
20 | Oberg K, Kvols L, Caplin M, et al (2004). Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol, 15, 966-73. DOI |
21 | Pisarek H, Pawlikowski M, Kunert-Radek J, Kubiak R, Winczyk K (2010). SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. Folia Histochem Cytobiol, 48, 142-7. |
22 | Rindi G, Arnold R, Bosman FT, et al (2010). Nomenclature and classification of neuroendocrine neoplasms of the digestive system, Eds Bosman FT, Carnerio F, Hruban RH, Theise ND, WHO classification of tumors of the digestive system. Fourth ed. WHO press, Lyon, pp. 13-4 . |
23 | Sclafani F, Carnaghi C, Di Tommaso L, et al (2011). Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors. Tumori, 97, 620-8. DOI |
24 | Zeng YJ, Liu L, Wu H, et al (2013). Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine tumors: analysis from a single-institution. Asian Pac J Cancer Prev, 14, 5775-81. DOI ScienceOn |
25 | Volante M, Brizzi MP, Faggiano A, et al (2007). Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol, 20, 1172-82. DOI |
26 | Yeniay L, Gurcu B, Unalp O, et al (2012). Prognostic value of somatostatin receptor-2 positivitiy in gastroenteropancreatic neuroendocrine tumors in reference to known prognostic factors. Turk J Gastroenterol, 23, 736-40. DOI |
27 | Zamora V, Cabanne A, Salanova R, et al (2010). Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis, 42, 220-5. DOI |
28 | Zhao WY, Zhuang C, Xu J, et al (2014). Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy. Am J Transl Res, 6, 831-40. |
29 | Zhou G, Sinnett-Smith J, Liu SH, et al (2014). Front Physiol, 5, 226. |
30 | Zhou Y, Jiang HG, Lu N, Lu BH, Chen ZH (2015). Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance. Asian Pac J Cancer Prev, 16, 1605-8. DOI |